Disease on EC 3.4.21.46 - complement factor D

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Effects of di(2-ethylhexyl)phthalate exposure on 1,2-dimethyhydrazine-induced colon tumor promotion in rats.
Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats.
Abortion, Habitual
Effect of the functional VEGFA-583C/T variant on vascular endothelial growth factor levels and the risk of recurrent spontaneous miscarriage.
Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland-derived vascular endothelial growth factor and prokineticin receptor polymorphisms.
Luteal phase defect is associated with impaired VEGF mRNA expression in the secretory phase endometrium.
miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9.
Recurrent miscarriage is associated with increased ghrelin mRNA expression in the endometrium- a case-control study.
Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss.
Vascular endothelial growth factor gene polymorphisms in North Indian patients with recurrent miscarriages.
Abortion, Incomplete
Factors related to completeness of medical abortion with mifepristone and misoprostol.
Abortion, Missed
Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) and Serum Placental Growth Factor (PlGF) as Biomarkers for Ectopic Pregnancy and Missed Abortion.
Abortion, Spontaneous
An Increase in Vascular Endothelial Growth Factor (VEGF) and VEGF Soluble Receptor-1 (sFlt-1) Are Associated with Early Recurrent Spontaneous Abortion.
Assessment of the transcription levels for the complement activation control system in eutopic endometrium in women with two or more consecutive miscarriages of unknown etiology.
Association of angiogenic cytokines (VEGF-A and VEGF-C) and clinical characteristic in women with unexplained recurrent miscarriage.
Association of serum levels of vascular endothelial growth factor and early ectopic pregnancy.
Association of Vascular Endothelial Growth Factor Gene Polymorphisms with Recurrent Spontaneous Abortion in Chinese Han Women.
Association of VEGF genetic polymorphisms with recurrent spontaneous abortion risk: a systematic review and meta-analysis.
Association study of vascular endothelial growth factor polymorphisms with the risk of recurrent spontaneous abortion.
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction.
Dynamics and reproductive effects of complement factors in the spontaneous abortion model of CBA/J×DBA/2 mice.
Effect of the functional VEGFA-583C/T variant on vascular endothelial growth factor levels and the risk of recurrent spontaneous miscarriage.
Elevation of Adipsin, a Complement Activating Factor, in the Mouse Placenta During Spontaneous Abortion.
Expression of ATF4 and VEGF in chorionic villus tissue in early spontaneous abortion.
Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland-derived vascular endothelial growth factor and prokineticin receptor polymorphisms.
Genetic variation in vascular endothelial growth factor gene and its association with recurrent spontaneous abortion.
Identification of specific vascular endothelial growth factor susceptible and protective haplotypes associated with recurrent spontaneous miscarriages.
Involvement of heparanase in vaginal and cesarean section deliveries.
Low VEGF expression in conceptus material and maternal serum AFP and ?-hCG levels as indicators of defective angiogenesis in first-trimester miscarriages.
Maternal serum vascular endothelial growth factor levels in early ectopic and intrauterine pregnancies after in vitro fertilization treatment.
MicroRNA-16 inhibits feto-maternal angiogenesis and causes recurrent spontaneous abortion by targeting vascular endothelial growth factor.
Polymorphisms in the vascular endothelial growth factor gene associated with recurrent spontaneous miscarriage.
Prenatal depression and stress - risk factors for placental pathology and spontaneous abortion.
Production of vascular endothelial growth factor and endothelin in the placenta and umbilical cord during normal and complicated pregnancy.
Regulation of Complement Activity via the Alternative Pathway in Placentas of Mouse Spontaneous Abortions.
Regulation of natural-killer cell cytotoxicity and enhancement of complement factors in the spontaneously aborted mouse placenta.
Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage.
Soluble Flt-1 and PlGF: New Markers of Early Pregnancy Loss?
The -2549 insertion/deletion polymorphism in the promoter region of the VEGFA gene in couples with idiopathic recurrent spontaneous abortion.
The association of second trimester biomarkers in amniotic fluid and fetal outcome.
The prevalence of combined vascular endothelial growth factor, endothelial nitric oxide synthase and thrombin-activatable fibrinolysis inhibitor genetic polymorphisms among Egyptian patients with recurrent spontaneous abortion.
The role of VEGF and its receptors in the etiology of early pregnancy loss.
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Vascular Endothelial Growth Factor (VEGF) and the VEGF Soluble Receptor-1 (sFlt-1) in Chorionic Villus Tissue from Chinese Women with Early Recurrent Spontaneous Abortion.
Vascular endothelial growth factor and recurrent spontaneous abortion: A meta-analysis.
Vascular endothelial growth factor gene polymorphisms and recurrent pregnancy loss.
[Growth factors are markers of placental insufficiency in third-trimester miscarriage].
Abortion, Threatened
Production of vascular endothelial growth factor and endothelin in the placenta and umbilical cord during normal and complicated pregnancy.
Soluble Flt-1 and PlGF: New Markers of Early Pregnancy Loss?
The relationship between the VEGF/sVEGFR-1 ratio and threatened abortion.
Abscess
Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF.
Acidosis
Accomplices of the Hypoxic Tumor Microenvironment Compromising Antitumor Immunity: Adenosine, Lactate, Acidosis, Vascular Endothelial Growth Factor, Potassium Ions, and Phosphatidylserine.
Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression.
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Multifunctional Albumin-MnO2 Nanoparticles Modulate Solid Tumor Microenvironment by Attenuating Hypoxia, Acidosis, Vascular Endothelial Growth Factor and Enhance Radiation Response.
Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells.
Acquired Immunodeficiency Syndrome
Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome.
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.
Acro-Osteolysis
Association of Acroosteolysis With Enhanced Osteoclastogenesis and Higher Blood Levels of Vascular Endothelial Growth Factor in Systemic Sclerosis.
Acromegaly
Plasma levels of vascular endothelial growth factor in patients with acromegaly.
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
The effects of growth hormone status on circulating levels of vascular growth factors.
Acute Coronary Syndrome
Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes.
Concentration of vascular endothelial growth factor in patients with acute coronary syndrome.
Gene electro transfer of plasmid encoding vascular endothelial growth factor for enhanced expression and perfusion in the ischemic swine heart.
Increased circulating placental growth factor during percutaneous coronary intervention is associated with applied radiocontrast agent.
Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.
Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes.
Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor.
Prognostic value of placental growth factor in patients with acute chest pain.
Wenyang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway.
[Evaluation of selected vascular active factors in patients after myocardial infarction subjected to cardiac rehabilitation].
Acute Kidney Injury
Acute renal failure during the "off" period after sunitinib administration: Possible mechanism of vascular endothelial growth factor cascade hyperactivation.
Complement depletion during haemofiltration with polyacrilonitrile membranes.
Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats.
Effects of histamine and the h2 receptor antagonist ranitidine on ischemia-induced acute renal failure: involvement of IL-6 and vascular endothelial growth factor.
Enhanced vascular endothelial growth factor and inflammatory cytokine removal with online hemodiafiltration over high-flux hemodialysis in sepsis-related acute kidney injury patients.
Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury.
Kinetics of Vascular Endothelial Growth Factor and Endothelin 1 Levels in Acute Kidney Injury.
Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats.
Protective effect of vascular endothelial growth factor against cardiopulmonary bypass-associated acute kidney injury in beagles.
Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration.
Acute Lung Injury
Bone marrow-derived mononuclear cell therapy in experimental pulmonary and extrapulmonary acute lung injury.
Effects of Vascular Endothelial Growth Factor in Recovery Phase of Acute Lung Injury in Mice.
Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF.
Protective role of vascular endothelial growth factor in endotoxin-induced acute lung injury in mice.
Pulmonary microvascular hyperpermeability and expression of vascular endothelial growth factor in smoke inhalation- and pneumonia-induced acute lung injury.
Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion.
Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury.
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.
The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival.
Variations in the Vascular Endothelial Growth Factor Pathway Predict Pulmonary Complications.
Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?
Vascular endothelial growth factor and related molecules in acute lung injury.
Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome.
Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury.
VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema.
Vegf-d promotes pulmonary oedema in hyperoxic acute lung injury.
[The protective effect of angiopoietin-1 on early acute lung injury induced by oleic acid in mice]
Adenocarcinoma
17beta-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells.
A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.
A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor.
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas.
A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor.
Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection.
Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Angiogenesis in normal tissue adjacent to colon cancer.
Angiogenic factors in normal endometrium and endometrial adenocarcinoma.
Angiogenic markers, neovascularization and malignant deformation of Barrett's esophagus.
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.
Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy.
Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma.
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas.
Betulinic acid inhibits the expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in human endometrial adenocarcinoma cells.
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers.
Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line.
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.
CD105 microvessels density, VEGF, EGFR-1 and c-erbB-2 and their prognostic correlation in different subtypes of cervical adenocarcinoma.
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays.
Cholesteryl oligoarginine delivering vascular endothelial growth factor sirna effectively inhibits tumor growth in colon adenocarcinoma.
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Clinical significance of immunohistochemical expression of hypoxia-inducible factor-1alpha as a prognostic marker in rectal adenocarcinoma.
Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Coexpression of vascular endothelial growth factor and its receptor KDR on gastric adenocarcinoma MGC803 cell line and stimulation of exogenous VEGF(165) to MGC803 cells.
Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6.
Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma.
Correlation between the immunohistochemical expressions of MMP-1, MMP-7 and VEGF and prognostic factors in colorectal adenocarcinoma.
Current status of novel agents in advanced gastroesophageal adenocarcinoma.
Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma.
Cytotoxic and Antimicrobial Evaluations of Novel Apoptotic and Anti-Angiogenic Spiro Cyclic 2-Oxindole Derivatives of 2-Amino-tetrahydroquinolin-5-one.
Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis.
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.
Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma.
Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity.
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3',5'-adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways.
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma.
Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor.
Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy.
Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation.
Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer.
Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer.
Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma.
Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma.
Expression levels and significance of hypoxia inducible factor-1 alpha and vascular endothelial growth factor in human colorectal adenocarcinoma.
Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma.
Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
Expression of CD44v3, erythropoietin and VEGF-C in gastric adenocarcinomas: correlations with clinicopathological features.
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction.
Expression of liver-type fatty-acid-binding protein, fatty acid synthase and vascular endothelial growth factor in human lung carcinoma.
EXPRESSION OF MUC2 GLYCOPROTEIN ANTIBODY AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN BARRETT'S MUCOSA.
Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis.
Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma.
Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas.
Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis.
Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration.
Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression.
Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma.
Expression of VEGF, EGFR, and IL-6 in Gastric Adenomas and Adenocarcinomas by Endoscopic Submucosal Dissection.
Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.
First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report.
Forkhead box P3 regulatory T cells coexisting with cancer associated fibroblasts are correlated with a poor outcome in lung adenocarcinoma.
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
Heparanase regulates in vitro VEGF-C expression and its clinical significance to pancreatic ductal cell adenocarcinoma.
Hepatocyte Growth Factor Mediated Cell Invasion in Pancreatic Cancer Cells Is Dependent on Neuropilin-1.
High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma.
High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.
High serum levels of Transforming Growth Factor-b1, Interleukin-10 and Vascular Endothelial Growth Factor in pancreatic adenocarcinoma patients.
High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma.
Hypoxia in human colorectal adenocarcinoma: Comparison between extrinsic and potential intrinsic hypoxia markers.
Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer.
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas.
Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.
Immunohistochemical study of vascular endothelial growth factor (VEGF) and matrilysin (MMP-7) in T1 adenocarcinoma of the colon and rectum to predict lymph node metastases or distant metastases.
Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma.
Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas.
Increased pro-angiogenic factors, infiltrating neutrophils and CD163(+) macrophages in bronchoalveolar lavage fluid from lung cancer patients.
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells.
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1.
Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats.
Lack of immunohistochemical detection of VEGF in prostate carcinoma.
Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer.
Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma.
Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma.
Lymphatic vessel density in pulmonary adenocarcinoma immunohistochemically evaluated with anti-podoplanin or anti-D2-40 antibody is correlated with lymphatic invasion or lymph node metastases.
Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa.
Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
MARKERS OF THE LUNG CANCER COMPLICATIONS.
Markers of tumour angiogenesis and tumour cells in bone marrow in gastric cancer patients.
Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Molecular determinants in targeted therapy for esophageal adenocarcinoma.
Molecular profiling of angiogenesis markers.
Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression.
Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma.
Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma.
Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis.
Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial ?5 integrin.
Novel cis-restricted ?-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro.
Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival.
Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.
Phosphatase of Regenerating Liver-3 Induces Angiogenesis by Increasing Extracellular Signal-Regulated Kinase Phosphorylation in Endometrial Adenocarcinoma.
Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study.
PlGF knockdown inhibited tumor survival and migration in gastric cancer cell via PI3K/Akt and p38MAPK pathways.
Possible involvement of tumor-producing VEGF-A in the recruitment of lymphatic endothelial progenitor cells from bone marrow.
Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer.
Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells.
Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer.
Prognostic Role of Protease-Activated Receptors 1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer.
Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung.
Protein kinase B phosphorylation correlates with vascular endothelial growth factor a and microvessel density in gastric adenocarcinoma.
Pulmonary adenocarcinoma angiogenesis.
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer.
Ramucirumab: A Review in Advanced Gastric Cancer.
Regulation of vascular endothelial growth factor expression by insulin-like growth factor-I in endometrial adenocarcinoma cells.
Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.
Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue.
Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas.
Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells.
Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma.
Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer.
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.
The ?-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor ?B signaling.
The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.
The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization.
The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma.
The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocarcinomas.
The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Tumor-Infiltrating Lymphocytes Express Vascular Endothelial Growth Factor in Renal Cell Carcinomas.
Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis.
Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells.
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma.
Vascular endothelial growth factor and survivin immunostaining in gastric adenocarcinoma.
Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma.
Vascular Endothelial Growth Factor Expression and Neovascularization in Non-Small Cell Lung Carcinoma.
Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression.
Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study.
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.
VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis.
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.
VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma.
VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these malignant tumors.
Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma.
[Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma]
[Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocarcinoma]
[The relationship of MMP-9, VEGF and PCNA expressions and their clinical significance in gastric adenocarcinoma]
[VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue.]
Adenocarcinoma of Lung
?-arrestin1 over-expression is associated with an unfavorable prognosis in lung adenocarcinomas and correlated with vascular endothelial growth factor.
Angiogenesis and phenotypic alteration of alveolar capillary endothelium in areas of neoplastic cell spread in primary lung adenocarcinoma.
Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
Branched ?-(1,4) glucans from Lentinula edodes (L10) in combination with radiation enhance cytotoxic effect on human lung adenocarcinoma through the Toll-like receptor 4 mediated induction of THP-1 differentiation/activation.
Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: they correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation.
Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Correlation between matrix metalloproteinase-9 and vascular endothelial growth factor expression in lung adenocarcinoma.
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma.
Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas.
Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection.
HoxB7 PROMOTES GROWTH AND METASTASIS OF LUNG ADENOCARCINOMA CELLS THROUGH REGULATION OF THE TGF-?/SMAD3 SIGNALING.
Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma.
Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism.
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma.
The Biophysical Property of A549 Cells Transferred by VEGF-D.
The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.
Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma.
Vascular endothelial growth factor and basic fibroblast growth factor in primary lung carcinomas and the incidence of metastases.
Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.
Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.
VEGF-A and its isoform VEGF(121) mRNA expression measured by quantitative real-time RT-PCR: correlation with F-18 FDG uptake and aggressiveness of lung adenocarcinoma: preliminary study.
VEGFR3 inhibition chemosensitizes lung adenocarcinoma A549 cells in the tumor-associated macrophage microenvironment through upregulation of p53 and PTEN.
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]
[Overexpression of p73 gene inhibits VEGF and bFGF mRNA expression in lung adenocarcinoma cell.]
[Relation of vascular endothelial growth factor-D expression to microvessel density, microlymphatic vessel density, and lymph-node metastasis of lung adenocarcinoma]
[The effect of TNP-470 on the proliferation and apoptosis of lung adenocarcinoma cells]
[VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue.]
Adenocarcinoma, Bronchiolo-Alveolar
Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung.
Stimulation of vascular endothelial growth factor gene transcription by all trans retinoic acid through Sp1 and Sp3 sites in human bronchioloalveolar carcinoma cells.
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]
Adenocarcinoma, Clear Cell
A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma.
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Adenocarcinoma, Follicular
Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration.
Adenocarcinoma, Mucinous
Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Adenoma
An immunohistochemical and ultrastructural study of pancreatic microcystic serous cyst adenoma with special reference to tumor-associated microvasculature and vascular endothelial growth factor in tumor cells.
Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Comparison of lymphatic vessel density and expression of VEGF-C and VEGF-D lymphangiogenic factors in Warthin's tumours and oncocytic adenomas.
Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients.
Effect of gamma knife radiosurgery on a pituitary gonadotroph adenoma: a histologic, immunohistochemical and electron microscopic study.
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid.
Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.
Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.
Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways.
Potential Red-Flag Identification of Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy.
The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Tumoral angiogenesis in both adrenal adenomas and nonadenomas: a promising computed tomography biomarker for diagnosis.
Vascular endothelial growth factor 1498C/T, 936C/T polymorphisms associated with increased risk of colorectal adenoma: a Chinese case-control study.
Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma.
[Association of vascular endothelial growth factor 936C/T polymorphism and the susceptibility to colorectal adenoma.]
[Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocarcinoma]
Adenoma, Pleomorphic
Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
The role of the VEGF-C/-D/flt-4 autocrine loop in the pathogenesis of salivary neoplasms.
Vascular endothelial growth factor immunoexpression is increased in malignant salivary gland tumors.
Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma.
Adenomatous Polyposis Coli
Colon cancer: a civilization disorder.
Adenomatous Polyps
VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.
Adenomyosis
Constitutive and tumor necrosis factor-?-induced activation of nuclear factor-?B in adenomyosis and its inhibition by andrographolide.
Effect of GnRHa on apoptosis and release of VEGF in endometrial cell cultures from patients with adenomyosis.
Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis.
Expression of Vascular Endothelial Growth Factor (VEGF), Hypoxia Inducible Factor-1alpha (HIF-1alpha), and Microvessel Density in Endometrial Tissue in Women With Adenomyosis.
Involvement of NADPH oxidase and NF-?B activation in CXCL1 induction by vascular endothelial growth factor in human endometrial epithelial cells of patients with adenomyosis.
Proangiogenic features in chronic pelvic pain caused by adenomyosis.
Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy.
Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis.
[Expression of vascular endothelial growth factor (VEGF) in uterine tissues as one of the mechanisms of algogenezis in adenomyosis, associated with chronic pelvic pain].
[Study on the expression of vascular endothelial growth factor in patients with adenomyosis of the uterus]
Adrenal Insufficiency
Reduction of maternal adrenal steroids results in increased VEGF protein without increased eNOS in the ovine placenta.
Adrenocortical Carcinoma
Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.
African Swine Fever
Serum Concentrations of Vascular Endothelial Growth Factor, Stromal Cell-Derived Factor, Nitric Oxide and Endothelial DNA Proliferation in Development of Microvascular Pathology in Acute African Swine Fever.
Agammaglobulinemia
Effects of circulating endothelial progenitor cells, serum vascular endothelial growth factor and hypogammaglobulinemia in Perthes disease.
Airway Obstruction
Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury.
Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients.
Remodeling in asthma and chronic obstructive pulmonary disease.
Albuminuria
Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease.
Angiopoietins: vascular growth factors looking for roles in glomeruli.
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss.
Effects of previous physical training on adriamycin nephropathy and its relationship with endothelial lesions and angiogenesis in the renal cortex.
Endothelial glycocalyx restoration by growth factors in diabetic nephropathy.
Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy.
Increased urine podocyte-associated messenger RNAs in severe obesity are evidence of podocyte injury.
Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.
Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
Mesangial immune complex glomerulonephritis due to complement factor D deficiency.
Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes.
Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Rapamycin prevents early steps of the development of diabetic nephropathy in rats.
Role of Complement Component C1q in the Onset of Preeclampsia in Mice.
Silencing of hypoxia-inducible factor-1? gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats.
The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.
The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus.
Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta1 and VEGF.
VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.
Alopecia
Alopecia in patients treated with molecularly targeted anticancer therapies.
Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss.
Loss of vascular endothelial growth factor in human alopecia hair follicles.
Vascular endothelial growth factor and its receptor may be one molecular mechanism for androgenetic alopecia.
Vascular Endothelial Growth Factor Protects CD200-Rich and CD34-Positive Hair Follicle Stem Cells Against Androgen-Induced Apoptosis Through the Phosphoinositide 3-Kinase/Akt Pathway in Patients With Androgenic Alopecia.
Alopecia Areata
Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
Altitude Sickness
Associations between Vascular Endothelial Growth Factor Gene Polymorphisms and Susceptibility to Acute Mountain Sickness.
B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness.
Cerebrovascular dynamics and vascular endothelial growth factor in acute mountain sickness.
Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness.
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness.
No correlation between plasma levels of vascular endothelial growth factor or its soluble receptor and acute mountain sickness.
Overexpression of genes associated with hypoxia in cattle adapted to Trans Himalayan region of Ladakh.
Plasma vascular endothelial growth factor in acute mountain sickness.
Variability in pulmonary function following rapid altitude ascent to the Amundsen-Scott South Pole station.
Vascular endothelial growth factor and acute mountain sickness.
[The expressions of VEGF and VEGFR signaling pathway in the bone marrow mononuclear cells with chronic mountain sickness].
Alveolar Bone Loss
Effects of formaldehyde on VEGF, MMP2, and Osteonectin levels in periodontal membrane and alveolar bone in the rats.
Role of Hyperplasia of Gingival Lymphatics in Periodontal Inflammation.
Alzheimer Disease
-1154G/A and -2578C/A polymorphisms of the vascular endothelial growth factor gene in Tunisian Alzheimer patients in relation to beta-amyloid (1-42) and total tau protein.
Amyloid-?(25-35), an amyloid-?(1-42) surrogate, and proinflammatory cytokines stimulate VEGF-A secretion by cultured, early passage, normoxic adult human cerebral astrocytes.
Association between promoter polymorphisms of vascular endothelial growth factor gene and sporadic Alzheimer's disease among Northern Chinese Han.
Association of serum vascular endothelial growth factor levels and cerebral microbleeds in patients with Alzheimer's disease.
Association of vascular endothelial growth factor levels in CSF and cerebral glucose metabolism across the Alzheimer's disease spectrum.
Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease.
Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer's disease.
Case-control study of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer's disease.
Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease.
Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate.
Dynamics of a heparin-binding domain of VEGF(165) complexed with its inhibitor triamterene.
Encapsulated VEGF-Secreting Cells Enhance Proliferation of Neuronal Progenitors in the Hippocampus of A?PP/Ps1 Mice.
Expression level of vascular endothelial growth factor in hippocampus is associated with cognitive impairment in patients with Alzheimer's disease.
From angiogenesis to neuropathology.
Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer's disease.
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia.
Increased serum concentrations of transforming growth factor-?1 (TGF-?1) in patients with Guillain-Barré syndrome.
Low serum VEGF levels are associated with Alzheimer's disease.
No Association of VEGF Polymorphims with Alzheimer's Disease.
Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer's Disease.
Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers.
The A? Peptides-Activated Calcium-Sensing Receptor Stimulates the Production and Secretion of Vascular Endothelial Growth Factor-A by Normoxic Adult Human Cortical Astrocytes.
The Amyloid-?42 Proxy, Amyloid-?25-35, Induces Normal Human Cerebral Astrocytes to Produce Amyloid-?42.
The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.
The Role of Mast Cells in Alzheimer's Disease.
The Role of Vascular Endothelial Growth Factor in Neurodegeneration and Cognitive Decline: Exploring Interactions With Biomarkers of Alzheimer Disease.
Vascular endothelial growth factor gene promoter polymorphisms and Alzheimer's disease risk: a meta-analysis.
Vascular endothelial growth factor improves the cognitive decline of Alzheimer's disease via concurrently inducing the expression of ADAM10 and reducing the expression of ?-site APP cleaving enzyme 1 in Tg2576 mice.
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia.
Vascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: A meta-analysis.
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.
VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment.
VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease.
[Levels of proinflammatory cytokines and vascular endothelial growth factor in patients with Alzheimer's disease and mild cognitive impairment].
Ameloblastoma
Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas.
Evaluation and Comparison of Vascular Endothelial Growth Factor Expression between Ameloblastoma and Keratocystic Odontogenic Tumor.
Expression of inducible nitric oxide synthase and vascular endothelial growth factor in ameloblastoma.
Amyloid Neuropathies
Serum vascular endothelial growth factor (VEGF) in the differential diagnosis of amyloid neuropathy and POEMS syndrome.
Amyloidosis
Effect of large-size dialysis membrane and hemofiltration/hemodiafiltration methods on long-term dialysis patients.
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
Transthyretin Ala36Pro mutation in a Chinese pedigree of familial transthyretin amyloidosis with elevated vitreous and serum vascular endothelial growth factor.
Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias.
Amyotrophic Lateral Sclerosis
ALS and oxidative stress: the neurovascular scenario.
Amyotrophic lateral sclerosis in pregnancy is associated with a vascular endothelial growth factor promoter genotype.
Association of polymorphisms in vascular endothelial growth factor gene with the age of onset of amyotrophic lateral sclerosis.
Brain-Derived Neurotrophic Factor Facilitates Functional Recovery from ALS-Cerebral Spinal Fluid-Induced Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line.
Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis.
Clinical and fundamental aspects of angiogenesis and anti-angiogenesis.
CSF concentrations of adipsin and adiponectin in patients with amyotrophic lateral sclerosis.
Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo.
Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration.
Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis.
Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons.
Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice.
Human umbilical cord blood cells transfected with VEGF and L(1)CAM do not differentiate into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis-a novel approach in stem cell therapy.
Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis.
Immunohistochemical studies of vascular endothelial growth factor in skin of patients with amyotrophic lateral sclerosis.
Impaired Cytoplasmic-Nuclear Transport of Hypoxia-Inducible Factor-1? in Amyotrophic Lateral Sclerosis.
Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3'-untranslated region.
Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression.
Post-spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VEGF and Ad5-ANG.
Roles of vascular endothelial growth factor in amyotrophic lateral sclerosis.
Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis.
Tandem Delivery of Multiple Therapeutic Genes Using Umbilical Cord Blood Cells Improves Symptomatic Outcomes in ALS.
Triple-Gene Therapy for Stroke: A Proof-of-Concept
Vascular endothelial growth factor and amyotrophic lateral sclerosis: The Interplay with exercise and non-invasive ventilation.
Vascular Endothelial Growth Factor Attenuates Neurodegenerative Changes in the NSC-34 Motor Neuron Cell Line Induced by Cerebrospinal Fluid of Sporadic Amyotrophic Lateral Sclerosis Patients.
Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis.
Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.
Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice.
Vascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegeneration.
VEGF and ALS.
VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis.
VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK.
Anal Gland Neoplasms
VEGF and 17-?-estradiol levels after tamoxifen administration in canine hepatoid gland adenomas and hepatoid gland epitheliomas.
Anaplasia
Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study.
Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.
Tenascin in Meningioma: Expression Is Correlated with Anaplasia, Vascular Endothelial Growth Factor Expression, and Peritumoral Edema But Not with Tumor Border Shape.
Androgen-Insensitivity Syndrome
Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice.
Anemia
Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF).
Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1.
Effect of large-size dialysis membrane and hemofiltration/hemodiafiltration methods on long-term dialysis patients.
Endostatin improves cancer-associated systemic syndrome in a lung cancer model.
Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients.
Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure.
Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia.
Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?
Myocardial vascular and metabolic adaptations in chronically anemic fetal sheep.
Peliosis hepatis associated with follicular lymphoma with a rise in vascular endothelial growth factor and anaemia of inflammation.
Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration.
Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells.
Study on the Effect of Severity of Maternal Iron Deficiency Anemia on Regulators of Angiogenesis in Placenta.
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis.
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
[A case of POEMS syndrome associated with Waldenström's macroglobulinemia and treated with lenalidomide].
[Molecular factors of angiogenesis in renal tissue of patients with chronic glomerulonephritis: association with nephrosclerosis and anemia]
Anemia, Aplastic
Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes.
Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia.
The regulatory roles of VEGF-Notch signaling pathway on aplastic anemia with kidney deficiency and blood stasis.
Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children.
[Bone marrow microvessel density and vascular endothelial growth factor expression in patients with aplastic anemia]
[Expression of vascular endothelial growth factor in patients with aplastic anemia and its significance]
[Serum Levels of sVCAM-1, IL-18 and VEGF in Patients with Aplastic Anemia and Their Clinical Significance.]
Anemia, Hemolytic
Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice.
Anemia, Iron-Deficiency
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Anemia, Sickle Cell
Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.
Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia.
Clinical relevance of vascular endothelial growth factor levels in sickle cell disease.
Cytokines and plasma factors in sickle cell disease.
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older.
Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells.
Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype.
The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment.
The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease.
Aneurysm
Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines.
Acceleration of aneurysm healing by P(DLLA-co-TMC)-coated coils enabling the controlled release of vascular endothelial growth factor.
Aneurysm embolization with biologically active coils: an animal study.
Concentration analysis of hypoxi-inducible factor-1?; and vascular endothelial growth factor in patients with aortic aneurysm at different stages and its clinical significance.
Delivery of human vascular endothelial growth factor with platinum coils enhances wall thickening and coil impregnation in a rat aneurysm model.
Embolization of a common carotid aneurysm with rhVEGF coupled to a pH-responsive chitosan in a rat model.
Endovascular treatment of aneurysms: healing mechanisms in a Swine model are associated with increased expression of matrix metalloproteinases, vascular cell adhesion molecule-1, and vascular endothelial growth factor, and decreased expression of tissue inhibitors of matrix metalloproteinases.
Erythropoietin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in an Aneurysm Neck After Coil Embolization by Modulating Vascular Endothelial Growth Factor.
Expression of angiogenesis factors and selected vascular wall matrix proteins in intracranial saccular aneurysms.
Heparin and Vascular Endothelial Growth Factor Loaded Poly(L-lactide-co-caprolactone) Nanofiber Covered Stent-Graft for Aneurysm Treatment.
Heterogeneous histomorphology, yet homogeneous vascular smooth muscle cell dedifferentiation, characterize human aneurysm disease.
Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease.
Rosuvastatin- and Heparin-Loaded Poly(l-lactide- co-caprolactone) Nanofiber Aneurysm Stent Promotes Endothelialization via Vascular Endothelial Growth Factor Type A Modulation.
Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice.
Vascular endothelial growth factor immobilized on platinum microcoils for the treatment of intracranial aneurysms: experimental rat model study.
Aneurysm, Dissecting
Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database.
Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma.
The multitasking role of macrophages in Stanford type A acute aortic dissection.
Aneurysm, Ruptured
Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man.
Angina Pectoris
Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris.
Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction.
Angina, Stable
High frequency home-based exercise decreases levels of vascular endothelial growth factor in patients with stable angina pectoris.
Interleukin-8 is associated with circulating CD133+ progenitor cells in acute myocardial infarction.
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma.
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals.
Angina, Unstable
Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina.
Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes.
Influence of preinfarction angina on the release kinetics of endothelial progenitor cells and cytokines during the week after infarction.
Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
[Concentration of plasma vascular endothelial growth factor and related factors in patients with unstable angina pectoris].
Angiodysplasia
Characterization of a Porcine Model for Von Willebrand Disease Type 1 and 3 Regarding Expression of Angiogenic Mediators in the Nonpregnant Female Reproductive Tract.
Increased expression of angiogenic factors in human colonic angiodysplasia.
Increased plasma vascular endothelial growth factor levels in patients with angiodysplasia.
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
The role of VEGF in angiodysplasia: an intervention study with thalidomide.
Angioedema
Elevated serum levels of TARC/CCL17, eotaxin-3/CCL26 and vascular endothelial growth factor in a patient with non-episodic angioedema associated with eosinophilia and granulomatous cutaneous reaction.
Vascular endothelial growth factor is involved in angioedema associated with eosinophilia.
Angiofibroma
Expression of vascular endothelial growth factor in Juvenile Angiofibroma.
Hormonal receptors and vascular endothelial growth factor in juvenile nasopharyngeal angiofibroma: immunohistochemical and tissue microarray analysis.
Hypoxia-Inducible Factor-1? (HIF-1?) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis.
Molecular angiogenic signaling in angiofibromas after embolization: implications for therapy.
Vessel density, proliferation, and immunolocalization of vascular endothelial growth factor in juvenile nasopharyngeal angiofibromas.
Angioid Streaks
Successful long-term management of choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: a case report.
Angiolipoma
Angiolipoma of the buccal mucosa: a possible role of mast cell-derived VEGF in its enhanced vascularity.
Angiomatosis, Bacillary
Differential effects of Bartonella henselae on human and feline macro- and micro-vascular endothelial cells.
Angiomyolipoma
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/-) Mice Is Superior to Everolimus Alone.
Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis.
Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms.
Aniridia
Analysis of protein composition and protein expression in the tear fluid of patients with congenital aniridia.
Anthrax
A "dock and lock" approach to preparation of targeted liposomes.
A "Dock and Lock" Approach to Preparation of Targeted Liposomes.
Anthrax Lethal Toxin Inhibits Growth of and Vascular Endothelial Growth Factor Release from Endothelial Cells Expressing the Human Herpes Virus 8 Viral G Protein Coupled Receptor.
Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.
Regulatory mechanisms of skeletal and connective tissue development and homeostasis - lessons from studies of human disorders.
Self-assembled "dock and lock" system for linking payloads to targeting proteins.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis.
Antiphospholipid Syndrome
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
Role of the Vitamin D in Leprosy.
Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome.
Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
Aortic Aneurysm
Concentration analysis of hypoxi-inducible factor-1?; and vascular endothelial growth factor in patients with aortic aneurysm at different stages and its clinical significance.
Perivascular Adipose Tissue-Derived PDGF-D Contributes to Aortic Aneurysm Formation During Obesity.
Aortic Aneurysm, Abdominal
Expression and localization of vascular endothelial growth factor in normal abdominal aorta and abdominal aortic aneurysm.
Expression of angiogenesis and angiogenic factors in human aortic vascular disease.
Polymorphisms of genes involved in the hypoxia signaling pathway and the development of abdominal aortic aneurysms or large-artery atherosclerosis.
Vascular endothelial growth factor enhances angiotensin II-induced aneurysm formation in apolipoprotein E-deficient mice.
Aortic Aneurysm, Thoracic
Curcumin attenuates the development of thoracic aortic aneurysm by inhibiting VEGF expression and inflammation.
Aortic Valve Stenosis
Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition.
The role of VEGF in the diabetic patients undergoing endovascular therapy of symptomatic aortic valve stenosis.
Arterial Occlusive Diseases
Designer zinc-finger proteins and their applications.
Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease.
Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo.
Arteriosclerosis
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis.
Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis.
The differentiation of mesenchymal stem cells to vascular cells regulated by the HMGB1/RAGE axis: its application in cell therapy for transplant arteriosclerosis.
Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis.
Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis.
[Effects of simvastatin on vasa vasorum and aortic endothelial function in rats]
Arteriovenous Fistula
Effects of brachytherapy on intimal hyperplasia in arteriovenous fistulas in a porcine model.
Evaluation of circulating vascular endothelial growth factor and soluble adhesion molecules as reliable predictors of native arteriovenous fistula thrombosis in chronic hemodialysis patients.
Investigation of the mechanism of dural arteriovenous fistula formation induced by high intracranial venous pressure in a rabbit model.
Arteriovenous Malformations
Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain.
Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia.
Effect of elevation of vascular endothelial growth factor level on exacerbation of hemorrhage in mouse brain arteriovenous malformation.
Effects of VEGF on phenotypic severity in children with hereditary hemorrhagic telangiectasia.
Expression of endothelial cell angiogenesis receptors in human cerebrovascular malformations.
Expression of platelet-derived growth factor ligand and receptor in cerebral arteriovenous and cavernous malformations.
Focal neurons: another source of vascular endothelial growth factor in brain arteriovenous malformation tissues?
Increased expression of angiogenic factors in cultured human brain arteriovenous malformation endothelial cells.
Increased expression of vascular endothelial growth factor and its receptor in enlarging brain arteriovenous malformations - a case report.
Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage.
Neurological surgery at the National Institutes of Health.
Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue.
Polymorphisms of the vascular endothelial growth factor A gene and susceptibility to sporadic brain arteriovenous malformation in a Chinese population.
Polymorphisms of VEGFA gene and susceptibility to hemorrhage risk of brain arteriovenous malformations in a Chinese population.
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Arteritis
A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis.
Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells.
Increased serum vascular endothelial growth factor level in Churg-Strauss syndrome.
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia.
Vascular endothelial growth factor gene polymorphisms in giant cell arteritis.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Arthritis
Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction.
Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis.
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
Complement factor D in serum. An indicator of glomerular filtration rate in chronic inflammatory arthritis.
Effect of Bone Marrow Mesenchymal Stem Cell Transplant on Synovial Proliferation in Rats With Type II Collagen-Induced Arthritis.
Effects of total saponins from Rhizoma Dioscoreae Nipponicae on expression of vascular endothelial growth factor and angiopoietin-2 and Tie-2 receptors in the synovium of rats with rheumatoid arthritis.
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis.
Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer.
Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis.
Fat-Produced Adipsin Regulates Inflammatory Arthritis.
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.
Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts.
Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models.
Intra-articular injection of platelet-richplasma reduces inflammation in a house swine model of rheumatoid arthritisof the knee joint.
Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog.
Local ice cryotherapy decreases synovial interleukin 6, interleukin 1?, vascular endothelial growth factor, prostaglandin-E2, and nuclear factor kappa B p65 in human knee arthritis: a controlled study.
Local synovial engagement of angiogenic Tie2 is associated with the development of persistent erosive rheumatoid arthritis in early arthritis patients.
Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing.
Myelodysplastic Syndrome Precedes the Onset of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome.
Placenta growth factor is not required for exercise-induced angiogenesis.
Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.
S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis.
Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides.
Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis.
Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis.
The angiogenic pathway "vascular endothelial growth factor/flk-1(KDR)-receptor" in rheumatoid arthritis and osteoarthritis.
The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis.
The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor.
The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis.
Vascular endothelial growth factor and its inhibitors.
Vascular endothelial growth factor C attenuates joint damage in chronic inflammatory arthritis by accelerating local lymphatic drainage in mice.
Vascular endothelial growth factor expression in arthritic joint is regulated by SAF-1 transcription factor.
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.
ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.
[Effects of qubi zhentong recipe on the expressions of IL-1beta, IL-8, and VEGF in the synovlal of rats with collagen-inducing arthritis].
[Relationship of tetramethylpyrazine on expression of vascular endothelial growth factor and development of adjuvant-induced arthritis in rats]
Arthritis, Experimental
An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
Effect of Bone Marrow Mesenchymal Stem Cell Transplant on Synovial Proliferation in Rats With Type II Collagen-Induced Arthritis.
Effects of cold-damp and hot-damp environment on VEGF and IL-1 expression in joint cartilage cells in adjuvant arthritis in rats.
Interleukin-35 attenuates collagen-induced arthritis through suppression of vascular endothelial growth factor and its receptors.
Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes.
Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice.
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).
Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis.
Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis.
Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.
[Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis].
[Up-regulated expressions of HIF-1?, VEGF and CD34 promote synovial angiogenesis in rats with adjuvant arthritis].
Arthritis, Infectious
TLR-2-mediated induction of vascular endothelial growth factor (VEGF) in cartilage in septic joint disease.
Arthritis, Juvenile
Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis.
Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis.
Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides.
The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis.
Arthritis, Psoriatic
Pathogenesis of psoriatic arthritis.
The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.
Vascular endothelial growth factor in patients with psoriatic arthritis.
Arthritis, Rheumatoid
A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor.
A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis.
Adeno-associated virus-delivered polycistronic microRNA-clusters for knockdown of vascular endothelial growth factor in vivo.
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators.
Age at onset of rheumatoid arthritis: association with polymorphisms in the vascular endothelial growth factor A(VEGFA) gene and an intergenic locus between matrix metalloproteinase (MMP) 1 and 3 genes.
Amelioration of collagen-induced arthritis in rats by nanogold.
An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.
Analysis of vascular endothelial growth factor (VEGF) functional variants in rheumatoid arthritis.
Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis.
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study.
Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes.
B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-?.
Biomarkers in Rheumatoid Arthritis, what is new?
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis.
Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis.
CD147 induces angiogenesis through vascular endothelial growth factor and hypoxiainducible transcription factor 1?-mediated pathway in rheumatoid arthritis.
CD147 induces up-regulation of vascular endothelial growth factor in U937-derived foam cells through PI3K/AKT pathway.
Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients.
Clinical Significance of Serum Levels of Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Patients with Rheumatoid Arthritis.
Cocoa polyphenols suppress TNF-?-induced vascular endothelial growth factor expression by inhibiting phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase-1 (MEK1) activities in mouse epidermal cells.
Correlation between circulating VEGF levels and disease activity in rheumatoid arthritis: a meta-analysis.
Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis.
Effect of electro-acupuncture on tumor necrosis factor-? and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis.
Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts.
Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis.
Effects of total saponins from Rhizoma Dioscoreae Nipponicae on expression of vascular endothelial growth factor and angiopoietin-2 and Tie-2 receptors in the synovium of rats with rheumatoid arthritis.
Electroacupuncture on ST36 and GB39 Acupoints Inhibits Synovial Angiogenesis via Downregulating HIF-1?/VEGF Expression in a Rat Model of Adjuvant Arthritis.
Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity.
Engagement of toll-like receptor 3 induces vascular endothelial growth factor and interleukin-8 in human rheumatoid synovial fibroblasts.
Expression of platelet-derived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis.
Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA).
Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis.
Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes.
Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes.
IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes.
IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis.
IL-35 prevent bone loss through promotion of bone formation and angiogenesis in rheumatoid arthritis.
IL-35, TNF-?, BAFF, and VEGF serum levels in patients with different rheumatic diseases.
Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis.
Immunohistochemical analysis of vascular endothelial growth factor expression in severe and destructive rheumatoid arthritis.
Increased expression of endocan in arthritic synovial tissues: effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes.
Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease.
Increasing production of matrix metalloproteinases, tumor necrosis factor-?, vascular endothelial growth factor and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts by different adiponectin isoforms in a concentration-dependent manner.
Inflammation and Lymphatic Function.
Infliximab: a review of its use in the management of rheumatoid arthritis.
Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts.
Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells.
Interaction Between Smoking and Polymorphism in the Promoter Region of the VEGFA Gene Is Associated with Ischemic Heart Disease and Myocardial Infarction in Rheumatoid Arthritis.
Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways.
Interleukin-35 attenuates collagen-induced arthritis through suppression of vascular endothelial growth factor and its receptors.
Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes.
Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and Doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis.
Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice.
Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.
Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid.
Phosphatidylserine inhibits inflammatory responses in interleukin-1?-stimulated fibroblast-like synoviocytes and alleviates carrageenan-induced arthritis in rat.
Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: differential effect of cigarette smoking.
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention.
Recent data on the role for angiogenesis in rheumatoid arthritis.
Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab.
Regulation of vascular endothelial junction stability and remodeling through Rap1-Rasip1 signaling.
Relationship between PI3K pathway and angiogenesis in CIA rat synovium.
Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis.
Serum concentrations of vascular endothelial growth factor in collagen diseases.
Serum vascular endothelial growth factor in late rheumatoid arthritis.
Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages.
Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis.
Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis.
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype.
Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis.
The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte.
The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis.
The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis.
The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study.
The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis.
The VEGFA -1154G/A polymorphism is associated with reduced risk of rheumatoid arthritis but not with systemic lupus erythematosus in Mexican women.
Vascular endothelial growth factor A (VEGFA) polymorphisms in Chinese patients with rheumatoid arthritis.
Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients.
Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts.
Vascular endothelial growth factor gene polymorphisms and rheumatoid arthritis.
Vascular endothelial growth factor in patients with rheumatoid arthritis.
Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells.
Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis.
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.
Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
VEGF Gene Polymorphisms Affect Serum Protein Levels and Alter Disease Activity and Synovial Lesions in Rheumatoid Arthritis.
[Characteristics of vascular morphology and vascular endothelial growth factor in patients with osteoarthritis and rheumatoid arthritis].
[Effect of 10-hydroxycamptotbecine on the expression of VEGF in rheumatoid arthritis synovial fibroblasts].
[Effect of strengthening Pi and activating blood circulation therapy on serum levels of adrenocorticotrophic hormone and vascular endothelial growth factor in rheumatoid arthritis patients]
[Effects of dioscornin tablet containing serum on NF-kappaB p65, STAT3, and VEGF mRNA expressions in rats' synovial cell strain RSC-364 induced by IL-17 and TNF-alpha].
[Effects of RNAi on cyclooxygenase-2 expression and biologic activity of human rheumatoid arthritis synovial fibroblasts]
[Polymorphism in the regulatory regions -?2578A and +C936T of the vascular endothelial growth factor (VEGF-A) gene in Russian women with rheumatoid arthritis].
[Relations of synovial angiogenesis and PTEN/PI3K/AKT signaling pathway in rats with adjuvant arthritis].
[Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis]
[Up-regulated expressions of HIF-1?, VEGF and CD34 promote synovial angiogenesis in rats with adjuvant arthritis].
Aspergillosis
Invasive aspergillosis associated with bevacizumab, a vascular endothelial growth factor inhibitor.
Asthma
A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack.
A potent antiangiogenic factor, endostatin prevents the development of asthma in a murine model.
A prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid, regulates vascular permeability by reducing vascular endothelial growth factor expression in asthma.
Abnormal histone methylation is responsible for increased vascular endothelial growth factor 165a secretion from airway smooth muscle cells in asthma.
Acute and chronic changes of vascular endothelial growth factor (VEGF) in induced sputum of toluene diisocyanate (TDI)-induced asthma patients.
Alveolar macrophage-derived VEGF contributes to allergic airway inflammation in a mouse asthma model.
Analysis of growth factors and inflammatory cytokines in exhaled breath condensate from asthmatic children.
Analysis of growth factors in serum and induced sputum from patients with asthma.
Analysis of vascular endothelial growth factor levels in induced sputum samples from patients with cough variant asthma.
Angiogenesis: a potentially critical part of remodelling in chronic airway diseases?
Association of vascular endothelial growth factor polymorphisms with asthma in tunisian children.
Association of Vascular Endothelial Growth Factor polymorphisms with childhood asthma, lung function, and airways responsiveness.
Associations between Th17-related inflammatory cytokines and asthma in adults: A Case-Control Study.
Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms.
Azithromycin Attenuates Fibroblast Growth Factors Induced Vascular Endothelial Growth Factor Via p38(MAPK) Signaling in Human Airway Smooth Muscle Cells.
Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma.
Chlamydophila pneumoniae triggers release of CCL20 and vascular endothelial growth factor from human bronchial epithelial cells through enhanced intracellular oxidative stress and MAPK activation.
Circulating and exhaled vascular endothelial growth factor in asthmatic pregnancy.
Clinical significance of plasma and serum vascular endothelial growth factor in asthma.
Clinical significance of serum vascular endothelial growth factor in young male asthma patients.
Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma.
Cough and asthma.
Effect of active vitamin D3 on VEGF-induced ADAM33 expression and proliferation in human airway smooth muscle cells: implications for asthma treatment.
Effects of academic exam stress on nasal leukotriene B4 and vascular endothelial growth factor in asthma and health.
Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma.
Effects of leukotriene receptor antagonists on vascular endothelial growth factor levels in asthma.
Evaluation of circulating vascular endothelial growth factor and its soluble receptors in patients suffering from persistent allergic rhinitis.
Evaluation of the PPAR-? Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils.
Expression of semaphorin 3A and neuropilin 1 in asthma.
Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma.
High vascular endothelial growth factor levels in NZW mice do not correlate with collagen deposition in allergic asthma.
IL-9 Induces VEGF Secretion from Human Mast Cells and IL-9/IL-9 Receptor Genes Are Overexpressed in Atopic Dermatitis.
Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.
Increased expression of tissue vascular endothelial growth factor and foetal liver kinase-1 receptor in seasonal allergic rhinitis and relevance to asthma component.
Increased synthesis of vascular endothelial growth factor in allergic airway inflammation in histidine decarboxylase knockout (HDC(-/-)) mice.
Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma.
Increased vascular permeability precedes cellular inflammation as asthma control deteriorates.
Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway.
Is VEGF a potential therapeutic target in asthma?
L-2-Oxothiazolidine-4-Carboxylic Acid or ?-Lipoic Acid Attenuates Airway Remodeling: Involvement of Nuclear Factor-?B (NF-?B), Nuclear Factor Erythroid 2p45-Related Factor-2 (Nrf2), and Hypoxia-Inducible Factor (HIF).
Markers of autoreactivity, coagulation and angiogenesis in patients with nonallergic asthma.
MFG-E8/integrin ?3 signaling contributes to airway inflammation response and airway remodeling in an ovalbumin-induced murine model of asthma.
Microvascular theory of exercise-induced bronchoconstriction in asthma: potential implication of vascular endothelial growth factor.
Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression.
Oncostatin M causes VEGF release from human airway smooth muscle: synergy with IL-1beta.
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) reduces vascular endothelial growth factor expression in allergen-induced airway inflammation.
Polymorphisms in the vascular endothelial growth factor (VEGF) gene associated with asthma.
Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma.
Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic.
Recombinant IGFBP-3 inhibits allergic lung inflammation, VEGF production, and vascular leak in a mouse model of asthma.
Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma.
Relationships of methacholine and adenosine monophosphate responsiveness with serum vascular endothelial growth factor in children with asthma.
Remodeling in asthma and chronic obstructive pulmonary disease.
Role of Inhaled Steroids in Vascular Airway Remodelling in Asthma and COPD.
Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants.
Role of the extracellular signal-regulated kinase 1/2 signaling pathway in regulating the secretion of bronchial smooth muscle cells in a rat model of chronic asthma.
Role of vascular endothelial growth factor antagonism on airway remodeling in asthma.
Roxithromycin inhibits VEGF-induced human airway smooth muscle cell proliferation: Opportunities for the treatment of asthma.
Serum vascular endothelial growth factor as a marker of asthma exacerbation.
Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation.
Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease.
TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids.
The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma.
Therapeutic perspectives in vascular remodeling in asthma and chronic obstructive pulmonary disease.
Thymoquinone inhibits inflammation, neoangiogenesis and vascular remodeling in asthma mice.
Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways.
Vascular biomarkers in asthma and COPD.
Vascular endothelial growth factor and cysteinyl leukotrienes in sputum supernatant of patients with asthma.
Vascular endothelial growth factor in patients with acute asthma.
Vascular endothelial growth factor induction by rhinovirus infection.
Vascular endothelial growth factor levels in induced sputum and emphysematous changes in smoking asthmatic patients.
Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma.
Vascular endothelial growth factor overexpression in induced sputum of children with bronchial asthma.
Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma.
Vascular remodeling is airway generation-specific in a primate model of chronic asthma.
Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation.
Vascular remodelling in asthma.
VEGF -2549 -2567 del18 polymorphism and irreversible bronchoconstriction in asthmatics.
VEGF serum concentration and irreversible bronchoconstriction in adult asthmatics.
VEGFA variants are associated with pre-school lung function, but not neonatal lung function.
[Effects of bacterial lipopolysaccharide on serum IL-4, serum IL-8 and pulmonary VEGF expression in mice with asthma].
[Modulation of Toll-like signal path of allergic asthma by CpG-ODNs from Bordetella pertussis].
[Potential mechanisms of airway remodeling initiated by activated thrombin in asthma]
[The effect of a vascular endothelial growth factor receptor inhibitor on airway inflammation and airway remodeling in a murine model of asthma]
[The research progress of relationship between the obstructive sleep apnea hypopnea syndrome and asthma].
[Vascular endothelial growth factor - structure, function and role in airways inflammation and the clinical course of asthma]
Astrocytoma
Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry.
Angiogenesis and its role in the behavior of astrocytic brain tumors.
Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas.
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series.
Blood-brain barrier breakdown in septic encephalopathy and brain tumours.
Co-existent pilocytic astrocytoma with acute B-cell leukemia within the cerebellum.
Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas.
Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance.
Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma.
Expression and hypoxic regulation of angiopoietins in human astrocytomas.
Expression and regulation of neuropilin-1 in human astrocytomas.
Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis.
Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas.
Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in association with neovascularization in human primary astrocytoma.
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
EXPRESSION OF INTERLEUKIN-8 (IL-8) RECEPTOR CXCR2 AND SUPPRESSOR OF CYTOKINE SIGNALING-3 (SOCS-3) IN ASTROCYTIC TUMORS.
Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors.
Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.
Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors.
Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients.
Expression of vascular endothelial growth factor (VEGF) and its two receptors in diffusely infiltrating astrocytomas and relationship to proliferative activity of tumor cells.
Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma.
Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma.
Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis.
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro.
Minimal change disease onset observed after bevacizumab administration.
miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study.
Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras.
Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells.
Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Production and interferon-gamma-mediated regulation of complement component C2 and factors B and D by the astroglioma cell line U105-MG.
Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.
PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas.
Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors.
Ras activation in astrocytomas and neurofibromas.
The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells.
The expressions of carbonic anhydrase 9 and vascular endothelial growth factor in astrocytic tumors predict a poor prognosis.
The importance of cell density in the interpretation of growth factor effects on collagenase IV activity release and extracellular matrix production from C6 astrocytoma cells.
The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.
Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?
Vascular endothelial growth factor and basic fibroblast growth factor expression positively correlates with angiogenesis and peritumoural brain oedema in astrocytoma.
Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario.
Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma.
Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy.
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
[A quantitative pathological study on angiogenesis, vascular endothelial growth factor and inducible nitric oxide synthase in astrocytomas]
[Expression of vascular endothelial growth factor in brain astrocytoma and its clinical evaluation]
[p53 and vascular endothelial growth factor expression in astrocytoma and their relation to angiogenesis]
Ataxia Telangiectasia
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival of gastric cancer.
Atherosclerosis
A study on the association of rs7950273 polymorphism in the PDGFD with ischaemic stroke in the Chinese Han population.
Altered in vitro endothelial repair and monocyte migration in obstructive sleep apnea: implication of VEGF and CRP.
Angiogenic Factors and Risks of Technique Failure and Cardiovascular Events in Patients Receiving Peritoneal Dialysis.
Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells.
Anti-inflammatory effect of glycosaminoglycan derived from Gryllus bimaculatus (a type of cricket, insect) on adjuvant-treated chronic arthritis rat model.
Anti-inflammatory Effect of Isaria sinclairii Glycosaminoglycan in an Adjuvant-treated Arthritis Rat Model.
Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor.
Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice.
Basic fibrobrast growth factor induces the secretion of vascular endothelial growth factor by human aortic smooth muscle cells but not by endothelial cells.
Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats.
Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose.
Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury.
Complement components as uremic toxins and their potential role as mediators of microinflammation.
Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis.
Cytokine-inducible growth factor gene expression in human umbilical endothelial cells.
Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants.
Diabetes mellitus-associated atherosclerosis : mechanisms involved and potential for pharmacological invention.
Effect of obstructive sleep apnea on carotid artery intima media thickness related to inflammation.
Effect of resveratrol on seric vascular endothelial growth factor concentrations during atherosclerosis.
Effect of simvastatin on expression of VEGF and TGF-?1 in atherosclerotic animal model of type 2 diabetes mellitus.
Effects of Lys-Glu-Trp peptide on cell-cell interactions and vascular endothelium proliferation under normal conditions and during atherosclerosis.
Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression.
Heritability for plasma VEGF concentration in the Stanislas family study.
High levels of oestrogen receptor-alpha in tumorigenesis: inhibition of cell growth and angiogenic factors.
HO-1 and VGEF gene expression in human arteries with advanced atherosclerosis.
Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages.
Identification of cis- and trans-Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels.
Increased placental growth factor (PlGF) concentrations in children and adolescents with obesity and the metabolic syndrome.
Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells.
Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis.
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.
Influences of Pinpoint Plantar Long-Wavelength Infrared Light Irradiation (Stress-Free Therapy) on Chorioretinal Hemodynamics, Atherosclerosis Factors, and Vascular Endothelial Growth Factor.
Inhibitions of vascular endothelial growth factor expression and foam cell formation by EGb 761, a special extract of Ginkgo biloba, in oxidatively modified low-density lipoprotein-induced human THP-1 monocytes cells.
Intercellular adhesion molecule-1 and vascular endothelial growth factor expression kinetics in macrophage-derived foam cells.
Lipoprotein-associated phosphatidylethanol increases the plasma concentration of vascular endothelial growth factor.
Nicotine potentiates vascular endothelial growth factor expression in balloon-injured rabbit aortas.
Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement.
Oxidised LDL decreases VEGFR-1 expression in human monocyte-derived macrophages.
PDGF-C and PDGF-D signaling in vascular diseases and animal models.
Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3.
Phosphatidylethanol in high density lipoproteins increases the vascular endothelial growth factor in smooth muscle cells.
Phosphatidylethanol mediates its effects on the vascular endothelial growth factor via HDL receptor in endothelial cells.
Placenta growth factor is not required for exercise-induced angiogenesis.
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness.
Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients.
Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.
Post-transcriptional regulation of VEGF expression by oxidised LDL in human macrophages.
Protective role of cytochrome P450 1A1 (CYP1A1) against benzo[a]pyrene-induced toxicity in mouse aorta.
Radiofrequency-enhanced vascular gene transduction and expression for intravascular MR imaging-guided therapy: feasibility study in pigs.
Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease.
Reduction of atherosclerosis in cholesterol-fed rabbits and decrease of expressions of intracellular adhesion molecule-1 and vascular endothelial growth factor in foam cells by a water-soluble fraction of Polygonum multiflorum.
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly.
Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor.
Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis.
Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia.
Serum Levels of Vascular Endothelial Growth Factor and Insulin-like Growth Factor Binding Protein-3 in Obstructive Sleep Apnea Patients: Effect of Continuous Positive Airway Pressure Treatment.
Serum VEGF--as a prognostic factor of atherosclerosis.
Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis.
Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor.
Soluble Fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation.
Systemic lupus erythematosus and atherosclerosis: Review of the literature.
The effects of growth hormone status on circulating levels of vascular growth factors.
The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models.
The impact of vascular endothelial growth factor +405 C/G polymorphism on long-term outcome and severity of coronary artery disease.
The NF-?B pathway: regulation of the instability of atherosclerotic plaques activated by Fg, Fb, and FDPs.
Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study).
Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study.
Variation in the vascular endothelial growth factor gene, carotid intima-media thickness and the risk of acute myocardial infarction.
Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.
Vascular endothelial growth factor and its inhibitors.
Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.
Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells.
Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells.
Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients.
Vascular endothelial growth factor promotes cell-cycle transition from G0 to G1 phase in subcultured endothelial cells of diabetic rat thoracic aorta.
Vascular endothelial growth factor-D expression in human atherosclerotic lesions.
Vascular endothelial growth factor-D is overexpressed in human cardiac allograft vasculopathy and diabetic atherosclerosis and induces endothelial permeability to low-density lipoproteins in vitro.
Vascular endothelial growth factor: angiogenesis, atherogenesis or both?
VEGF and therapeutic opportunities in cardiovascular diseases.
VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor.
VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration.
VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kappaB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits.
Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice.
Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL.
[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]
[What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management]
Atrial Fibrillation
Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation.
Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke.
Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis?
Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy.
Atypical Hemolytic Uremic Syndrome
Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Autoimmune Diseases
Active Vaccination With EMMPRIN-Derived Multiple Antigenic Peptide (161-MAP) Reduces Angiogenesis in a Dextran Sodium Sulfate (DSS)-Induced Colitis Model.
Chronic and non-healing wounds: The story of vascular endothelial growth factor.
Investigation on association between five common polymorphisms in vascular endothelial growth factor and prototypes of autoimmune diseases.
Luteolin inhibits human keratinocyte activation and decreases NF-?B induction that is increased in psoriatic skin.
Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases.
Vascular endothelial growth factor (VEGF) in autoimmune diseases.
Azoospermia
Caspase-3 and VEGF immunopositivity in seminiferous tubule germ cells in cases of obstructive and non-obstructive azoospermia in smokers versus non-smokers.
Bacteremia
Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome.
Bacterial Infections
Bacterial induction of pleural mesothelial monolayer barrier dysfunction.
Functional deficiency of complement factor D in a monozygous twin.
Infection of human brain vascular pericytes (HBVPs) by Bartonella henselae.
Lipoprotein-associated phospholipase A2, myeloperoxidase and vascular endothelial growth factor - predictors of high vascular risk in respiratory bacterial infections.
Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome.
Barrett Esophagus
Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Bartonella Infections
Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor.
Behcet Syndrome
Association of vascular endothelial growth factor gene polymorphisms with behcet disease in a Korean population.
EFFECT OF INTRAVITREAL METHOTREXATE AND AQUEOUS HUMOR CYTOKINE LEVELS IN REFRACTORY RETINAL VASCULITIS IN BEHCET DISEASE.
The role of heat shock protein 60, vascular endothelial growth factor and antiphospholipid antibodies in Behçet disease.
beta-Thalassemia
Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia.
Vascular endothelial growth factor and pulmonary hypertension in children with beta thalassemia major.
Vascular endothelial growth factor in children with thalassemia major.
Bile Duct Neoplasms
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Biliary Atresia
Genetic Variation in the Vascular Endothelial Growth Factor Gene is Associated With Biliary Atresia.
Biliary Tract Neoplasms
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma.
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Bisphosphonate-Associated Osteonecrosis of the Jaw
Genetic association between VEGF polymorphisms and BRONJ in the Korean population.
Blast Crisis
Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
Blindness
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.
Adenosine receptors and caffeine in retinopathy of prematurity.
An endothelin type a receptor antagonist reverses upregulated VEGF and icam-1 levels in streptozotocin-induced diabetic rat retina.
Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity.
Clinical application of therapies targeting VEGF.
Curcumolide, a unique sesquiterpenoid from Curcuma wenyujin displays anti-angiogenic activity and attenuates ischemia-induced retinal neovascularization.
Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.
Effects of HGF and KGF gene silencing on vascular endothelial growth factor and its receptors in rat ultraviolet radiation?induced corneal neovascularization.
Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy.
Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide.
Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells.
Regulation of tight junctions and loss of barrier function in pathophysiology.
Requirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injury.
RETHINKING STOP-ROP: IS IT WORTHWHILE TRYING TO MODULATE EXCESSIVE VEGF LEVELS IN PRETHRESHOLD ROP EYES BY SYSTEMIC INTERVENTION?: A Review of the Role of Oxygen, Light Adaptation State, and Anemia in Prethreshold ROP.
Retinal hypoxia induces vascular endothelial growth factor through induction of estrogen-related receptor ?.
Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells.
Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor.
TCCR/WSX-1 is a novel angiogenic factor in age-related macular degeneration.
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy.
VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases.
VEGF-Production by CCR2-Dependent Macrophages Contributes to Laser-Induced Choroidal Neovascularization.
Vitreous TIMP-1 levels associate with neovascularization and TGF-?2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy.
[New drug treatment for age-related macular degeneration]
Blister
Histopathological and Molecular Changes in the Rabbit Cornea From Arsenical Vesicant Lewisite Exposure.
Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase.
Severe generalized pustular psoriasis accompanied by bullae formation with increased serum vascular endothelial growth factor level.
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report.
UV radiation induces the release of angiopoietin-2 from dermal microvascular endothelial cells.
Bone Diseases
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
Expression of human VEGF(121) cDNA in mouse bone marrow stromal cells.
Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Bone Resorption
A Pilot, Randomized Study in Women of Nutrition-Related Clinical Chemistry at 6 Weeks after Roux en Y Gastric Bypass: Comparison of Two Nutrition Support Plans.
Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice.
IL6 receptor blockade preserves articular cartilage and increases bone volume following ischemic osteonecrosis in immature mice.
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts.
Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption.
Bowen's Disease
Expression of hypoxia-inducible factor-1?, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
Brain Contusion
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion.
Very early expression of vascular endothelial growth factor in brain oedema tissue associated with brain contusion.
Brain Death
Comparison of Vascular Endothelial Growth Factor Concentration in Porcine Kidneys Removed From Living Donors After Cardiac and Brain Death.
Brain Diseases
Apatinib-induced hyperammonemic encephalopathy.
Could increased vascular endothelial growth factor induced by interleukin 17 be the cause of posterior reversible encephalopathy syndrome in systemic lupus erythematosus?
Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability.
Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy.
Protective Effects of Tetramethylpyrazine on Cerebrovascular Regulations in Rats with Chronic Alcoholic Encephalopathy.
Reversible Encephalopathy after Cardiac Transplantation: Histologic Evidence of Endothelial Activation, T-cell Specific Trafficking, and Vascular Endothelial Growth Factor Expression.
Role of interleukin-6 and vascular endothelial growth factor in Henoch-Schönlein purpura with posterior reversible encephalopathy syndrome.
Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) levels in the cerebrospinal fluid of children with influenza-associated encephalopathy.
Vascular endothelial growth factor mediates vasogenic edema in acute lead encephalopathy.
Brain Edema
13-Methyltetradecanoic acid mitigates cerebral ischemia/reperfusion injury.
A pre-injury high ethanol intake in rats promotes brain edema following traumatic brain injury.
Alterations in the expression of vascular endothelial growth factor in the rat brain following gamma knife surgery.
Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.
Anti-vasopermeability effects of PEDF in retinal-renal disorders.
Antiangiogenic therapy for glioblastoma.
Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.
Apatinib in refractory radiation-induced brain edema: A case report.
AQP-4 in peritumoral edematous tissue is correlated with the degree of glioma and with expression of VEGF and HIF-alpha.
Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosed glioblastoma: an immunohistochemical study.
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion.
Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis.
Bevacizumab for the treatment of post-stereotactic radiosurgery adverse radiation effect.
Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia.
Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume.
Endothelin systems in the brain: involvement in pathophysiological responses of damaged nerve tissues.
Evaluating the molecular basis for acute mountain sickness: hypoxia response gene expression patterns in warfighters and murine populations.
Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.
Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway.
Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness.
Hypoxia-inducible factor and vascular endothelial growth factor are targets of dietary soy during acute stroke in female rats.
Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema.
Lesion Size Is Exacerbated in Hypoxic Rats Whereas Hypoxia-Inducible Factor-1 Alpha and Vascular Endothelial Growth Factor Increase in Injured Normoxic Rats: A Prospective Cohort Study of Secondary Hypoxia in Focal Traumatic Brain Injury.
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor.
No correlation between plasma levels of vascular endothelial growth factor or its soluble receptor and acute mountain sickness.
Pathophysiology of Meningioma Growth in Pregnancy.
Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply.
Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway.
Protection of Vascular Endothelial Growth Factor to Brain Edema Following Intracerebral Hemorrhage and Its Involved Mechanisms: Effect of Aquaporin-4.
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats.
Regulations of astrocytic functions by endothelins: roles in the pathophysiological responses of damaged brains.
Surgical brain injury and edema prevention.
Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.
The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas.
Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema.
Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis.
Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction.
Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain.
Vascular Endothelial Growth Factor in Brain Edema Formation After Subarachnoid Hemorrhage.
Vascular endothelial growth factor in tuberculous meningitis.
Vascular endothelial growth factor is associated with blood brain barrier dysfunction in eosinophilic meningitis caused by Angiostrongylus cantonensis infection.
Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury.
[Correlation between vascular endothelial growth factor and peritumoural edema in meningiomas]
[Efficiency of integrin ?v?3 inhibitor Cilengitide in acute cerebral ischemia in rats].
[Micro-ribonucleic acids participate in electroacupuncture intervention-induced improvement of ischemic stroke].
[Small interfering RNA (siRNA) targeting vascular endothelial growth factor inhibits vascular leakage in brain of rats exposed to high altitude]
[Vascular endothelial factor of meningomas and peritumoural vasogenic brain edema]
Brain Infarction
Association between kinase insert domain-containing receptor gene polymorphisms and silent brain infarction: a Korean study.
Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells.
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Vascular protection and restorative therapy in ischemic stroke.
Brain Injuries
Adeno-associated viral vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice.
Adenovirus-mediated brain-derived neurotrophic factor expression regulated by hypoxia response element protects brain from injury of transient middle cerebral artery occlusion in mice.
Anti-Vascular Endothelial Growth Factor Treatment Suppresses Early Brain Injury After Subarachnoid Hemorrhage in Mice.
Astrocytes-derived VEGF exacerbates the microvascular damage of late delayed RBI.
Carbon monoxide potentiation of L-type Ca2+ channel activity increases HIF-1?-independent VEGF expression via an AMPK?/SIRT1-mediated PGC-1?/ERR? axis.
Correlation between magnetic resonance perfusion weighted imaging of radiation brain injury and pathology.
Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury.
Dynamic Changes of Vascular Endothelial Growth Factor and Angiopoietin-1 in Association With Circulating Endothelial Progenitor Cells After Severe Traumatic Brain Injury.
Effect of Combination Therapy with Neuroprotective and Vasoprotective Agents on Cerebral Ischemia.
Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke.
Neurogenic effect of VEGF is related to increase of astrocytes transdifferentiation into new mature neurons in rat brains after stroke.
Neuroprotective Effects of Vascular Endothelial Growth Factor Following Hypoxic Ischemic Brain Injury in Neonatal Rats.
Neuroprotective effects of VEGF administration after focal cerebral ischemia/reperfusion: Dose response and time window.
Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats.
Promoting neuroregeneration after perinatal arterial ischemic stroke: neurotrophic factors and mesenchymal stem cells.
Protection of granulocyte-colony stimulating factor to hemorrhagic brain injuries and its involved mechanisms: effects of vascular endothelial growth factor and aquaporin-4.
Rapid, reversible modulation of blood-brain barrier P-glycoprotein transport activity by vascular endothelial growth factor.
Role of PDGF-D and PDGFR-? in neuroinflammation in experimental ICH mice model.
Signaling pathways for early brain injury after subarachnoid hemorrhage.
Transplantation of human umbilical cord blood mesenchymal stem cells to treat a rat model of traumatic brain injury.
Vascular endothelial growth factor (vascular permeability factor) expression in injured rat brain.
Vascular endothelial growth factor A promotes platelet adhesion to collagen IV and causes early brain injury after subarachnoid hemorrhage.
Vascular endothelial growth factor is neuroprotective against ischemic brain injury by inhibiting scavenger receptor A expression on microglia.
Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase.
Vascular endothelial growth factor: an attractive target in the treatment of hypoxic/ischemic brain injury.
VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway.
VEGF overexpression in the astroglial cells of rat brainstem following ozone exposure.
[Expression changes of Ang-1, Ang-2, Tie-2 and VEGF in co-culturing of endothelial cells and astrocytes after irradiation by X-ray and their significances].
[The evaluation neuropsychological development in preterm infants with hypoxic brain injury].
Brain Injuries, Traumatic
Collagen-chitosan scaffold impregnated with bone marrow mesenchymal stem cells for treatment of traumatic brain injury.
Differential expression of capillary VEGF isoforms following traumatic brain injury.
Dynamic Changes of Vascular Endothelial Growth Factor and Angiopoietin-1 in Association With Circulating Endothelial Progenitor Cells After Severe Traumatic Brain Injury.
Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury.
Erythropoietin Mediates Neurobehavioral Recovery and Neurovascular Remodeling Following Traumatic Brain Injury in Rats by Increasing Expression of Vascular Endothelial Growth Factor.
Hippocampal Neurogenesis after Traumatic Brain Injury Is Mediated by Vascular Endothelial Growth Factor Receptor-2 and the Raf/MEK/ERK Cascade.
Histopathological changes in the choroid plexus after traumatic brain injury in the rats: a histologic and immunohistochemical study.
Increased Expression of Vascular Endothelial Growth Factor Attenuates Contusion Necrosis without Influencing Contusion Edema after Traumatic Brain Injury in Rats.
Lesion Size Is Exacerbated in Hypoxic Rats Whereas Hypoxia-Inducible Factor-1 Alpha and Vascular Endothelial Growth Factor Increase in Injured Normoxic Rats: A Prospective Cohort Study of Secondary Hypoxia in Focal Traumatic Brain Injury.
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Pathomorphology of inflammatory response following traumatic brain injury, serum values of interleukins, and gene polymorphisms.
Release of VEGF and FGF in the extracellular space following severe subarachnoidal haemorrhage or traumatic head injury in humans.
Role of vascular endothelial growth factor in blood-brain barrier breakdown and angiogenesis in brain trauma.
Subacute treatment with vascular endothelial growth factor after traumatic brain injury increases angiogenesis and gliogenesis.
The role of vascular endothelial growth factor and vascular endothelial growth inhibitor in clinical outcome of traumatic brain injury.
Time-dependent changes of protein biomarker levels in the cerebrospinal fluid after blast traumatic brain injury.
Vascular endothelial growth factor increases neurogenesis after traumatic brain injury.
Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children.
Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury.
[Nrp-1 expression in healing process of traumatic brain injury combined with tibial fracture].
Brain Injury, Chronic
Huanglian-Jie-Du-Tang Extract Protects against Chronic Brain Injury after Focal Cerebral Ischemia via Hypoxia-Inducible-Factor-1?-Regulated Vascular Endothelial Growth Factor Signaling in Mice.
Brain Ischemia
Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebral ischemia.
Adeno-associated viral vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice.
Aggravation of hemorrhagic transformation by early intraarterial infusion of low-dose vascular endothelial growth factor after transient focal cerebral ischemia in rats.
Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia.
Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.
Basic Fibroblast Growth Factor Protects Astrocytes Against Ischemia/Reperfusion Injury by Upregulating the Caveolin-1/VEGF Signaling Pathway.
Changes in serum vascular endothelial growth factor and endostatin concentrations associated with circulating endothelial progenitor cells after acute ischemic stroke.
Combined treatment of vascular endothelial growth factor and human neural stem cells in experimental focal cerebral ischemia.
Early expressions of hypoxia-inducible factor 1alpha and vascular endothelial growth factor increase the neuronal plasticity of activated endogenous neural stem cells after focal cerebral ischemia.
Effect of bone marrow stromal cell transplantation on neurologic function and expression of VEGF in rats with focal cerebral ischemia.
Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia.
Effects of the Thioredoxin-1 Inhibitor PX-12 on Blood-Brain Barrier Permeability in the Early Stage of Focal Cerebral Ischemia.
Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex.
Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia.
Enhanced expression of vascular endothelial growth factor receptor-3 in the subventricular zone of stroke-lesioned rats.
Enhancement of expression of vascular endothelial growth factor after adeno-associated virus gene transfer is associated with improvement of brain ischemia injury in the gerbil.
Expression of angiopoietin-2 and vascular endothelial growth factor in mice cerebral cortex after permanent focal cerebral ischemia.
Expression of brain-specific angiogenesis inhibitor 2 (BAI2) in normal and ischemic brain: involvement of BAI2 in the ischemia-induced brain angiogenesis.
Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat.
Expression of VEGF and neural repair after alprostadil treatment in a rat model of sciatic nerve crush injury.
HIF-1 alpha and VEGF expression after transient global cerebral ischemia.
Huanglian-Jie-Du-Tang Extract Protects against Chronic Brain Injury after Focal Cerebral Ischemia via Hypoxia-Inducible-Factor-1?-Regulated Vascular Endothelial Growth Factor Signaling in Mice.
Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model.
Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia.
Hypoxia-Inducible Factor 1-?-AA-Modified Bone Marrow Stem Cells Protect PC12 Cells from Hypoxia-Induced Apoptosis, Partially Through VEGF/PI3K/Akt/FoxO1 Pathway.
Hypoxic Preconditioning Increases Blood-Brain Barrier Disruption in the Early Stages of Cerebral Ischemia.
Impacts of N-Butylphthalide on expression of growth factors in rats with focal cerebral ischemia.
Implications of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man.
Improving Cerebral Blood Flow Through Liposomal Delivery of Angiogenic Peptides: Potential of ¹?F-FDG PET Imaging in Ischemic Stroke Treatment.
Increased protein and mRNA expression of endostatin in the ischemic brain tissue of rabbits after middle cerebral artery occlusion.
Induction of vascular endothelial growth factor and hypoxia-inducible factor-1alpha by global ischemia in rat brain.
Induction of vascular endothelial growth factor receptor-3 expression in perivascular cells of the ischemic core following focal cerebral ischemia in rats.
Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats.
Induction of vascular endothelial growth factor receptors and phosphatidylinositol 3'-kinase/Akt signaling by global cerebral ischemia in the rat.
Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment.
Intraventricular vascular endothelial growth factor antibody increases infarct volume following transient cerebral ischemia.
Investigation of the mechanism of dural arteriovenous fistula formation induced by high intracranial venous pressure in a rabbit model.
Met-Controlled Allosteric Module of Neural Generation as A New Therapeutic Target in Rodent Brain Ischemia.
Microglia preconditioned by oxygen-glucose deprivation promote functional recovery in ischemic rats.
Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat.
Optimal dose of plasmid vascular endothelial growth factor for enhancement of angiogenesis in the rat brain ischemia model.
Regenerative repair of Pifithrin-? in cerebral ischemia via VEGF dependent manner.
Retraction: Vascular endothelial growth factor in cerebral ischemia.
Transplantation of vascular endothelial growth factor-transfected neural stem cells into the rat brain provides neuroprotection after transient focal cerebral ischemia.
Vascular endothelial growth factor aggravates cerebral ischemia and reperfusion-induced blood-brain-barrier disruption through regulating LOC102640519/HOXC13/ZO-1 signaling.
Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia.
Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat.
Vascular endothelial growth factor gene expression in middle cerebral artery occlusion in the rat.
Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduce infarction volume in rat brain ischemia.
Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat.
Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia.
Vascular endothelial growth factor in cerebral ischemia.
Vascular endothelial growth factor promotes pericyte coverage of brain capillaries, improves cerebral blood flow during subsequent focal cerebral ischemia, and preserves the metabolic penumbra.
Vascular endothelial growth factor upregulation in transient global ischemia induced by cardiac arrest and resuscitation in rat brain.
VEGF Ameliorates Cognitive Impairment in In Vivo and In Vitro Ischemia via Improving Neuronal Viability and Function.
VEGF promotes angiogenesis and functional recovery in stroke rats.
VEGF protects brain against focal ischemia without increasing blood--brain permeability when administered intracerebroventricularly.
[Effect of Electroacupuncture Combined with Polysaccharide of Gastrodia elata Blume on Ex- pression of Brain Derived Neurotrophic Factor and Vascular Endothelial Growth Factor in the Paraventricular Nucleus of Hypothalamus in Cerebral Ischemia Rat].
[Effect of scalp acupuncture on learning ability and hippocampal VEGF expression in chronic cerebral ischemia rats].
[Effects of Electroacupuncture and Intracerebral Injection of VEGF on Caspase12, Caspase3, and GRP78 Genes in Rats with Cerebral Ischemia-Reperfusion Injury].
[Effects of electroacupuncture combined with compound Salviae Miltiorrhizae tablet on the expressions of brain derived neurotrophic factor and vascular endothelial growth factor in hippocampus CA1 of chronic cerebral ischemia rats].
[Efficiency of integrin ?v?3 inhibitor Cilengitide in acute cerebral ischemia in rats].
[Electroacupuncture Combined with Intracerebral Injection of VEGF Improves Neurological Dysfunction Possibly by Down-regulating Expression of Endoplasmic Reticulum Stress Related Proteins ATF 6, etc. in Cerebral Ischemia-reperfusion Injury Rats].
[Expression and function of vascular endothelial growth factor and angiopoietins in rat brain after cerebral ischemia].
[Molecular markers of endothelial damage in patients with Parkinson's disease].
[Progranulin].
[Recent advance in experimental study of cerebral ischemia treated by vascular endothelial growth factor]
[Recombinant AAV1 mediated vascular endothelial growth factor gene expression promotes angiogenesis and improves neural function: experiment with rats]
Brain Neoplasms
A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
Angiogenic factors in plasma of brain tumour patients.
Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?
Antiangiogenic Therapy of High-Grade Gliomas.
Antidepressant hyperforin up-regulates VEGF in CNS tumour cells.
Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model.
Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay.
Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.
Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor.
Changes in VEGF expression and in the vasculature during the growth of early-stage ethylnitrosourea-induced malignant astrocytomas in rats.
Complex Oncogenic Signaling Networks Regulate Brain Tumor-Initiating Cells and Their Progenies: Pivotal Roles of Wild-Type EGFR, EGFRvIII Mutant and Hedgehog Cascades and Novel Multitargeted Therapies.
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.
Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.
Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.
Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis.
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice.
Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.
Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells.
Expression and distribution of vascular endothelial growth factor protein in human brain tumors.
Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.
Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors.
Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.
Expression of vascular endothelial growth factor in human brain tumors.
Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.
Expression of vascular endothelial growth-factor in the cyst fluid of human cerebral gliomas.
Expression of VEGF and its receptor genes in intracranial schwannomas.
Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma.
Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.
Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis.
Lactate administration reproduces specific brain and liver exercise-related changes.
Metastatic brain mass caused by slow-growing small-cell lung cancer: differential vascular endothelial growth factor expression in primary and metastatic tumor.
Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor.
Plasmalemmal vesicle associated protein-1 is a novel marker implicated in brain tumor angiogenesis.
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas.
Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy.
Serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in children with brain tumours.
Simulating vasogenic brain edema using chronic VEGF infusion.
The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor.
Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
Update on the use of angiogenesis inhibitors in adult patients with brain tumors.
Vascular abnormalities in surgical specimens obtained from the resected focus of intractable epilepsy.
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression.
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.
Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors.
VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly.
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
VEGF Trap induces antiglioma effect at different stages of disease.
VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells.
VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy.
YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
Breast Carcinoma In Situ
Angiogenesis and VEGF expression in pre-invasive lesions of the human breast.
[Expression of vascular endothelial growth factor in different breast tissues and clinical significance thereof]
Breast Neoplasms
17beta-estradiol inhibits forskolin-induced vascular endothelial growth factor promoter in MCF-7 breast adenocarcinoma cells.
99m-Tc-MDP-Scintimammography in the evaluation of breast masses or tumor angiogenesis.
?IIb?3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells.
?vß3-Integrin-Targeted Magnetic Resonance Imaging for the Assessment of Early Antiangiogenic Therapy Effects in Orthotopic Breast Cancer Xenografts.
A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk.
A Common and Functional Gene Variant in the Vascular Endothelial Growth Factor A Predicts Clinical Outcome in Early-Stage Breast Cancer.
A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers.
A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
A general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly.
A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Dissemination to Bone of Breast Cancer Tumor Cells.
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
A new impedimetric biosensor utilizing VEGF receptor-1 (Flt-1): early diagnosis of vascular endothelial growth factor in breast cancer.
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
A physiologic imaging pilot study of breast cancer treated with AZD2171.
A potential role for vascular endothelial growth factor-D as an autocrine growth factor for human breast carcinoma cells.
A practical and sensitive method of quantitating lymphangiogenesis in vivo.
A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts.
A review on the role of VEGF in Tamoxifen resistance.
Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Activation of GPR120 promotes the metastasis of breast cancer through the PI3K/Akt/NF-?B signaling pathway.
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin.
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Alcohol promotes mammary tumor growth through activation of VEGF-dependent tumor angiogenesis.
Alteration in platelet function in patients with early breast cancer.
An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer.
Analysis of the Relationship Between Ultrasound of Breast Cancer DOT-SDI and the Expression of MVD, VEGF and HIF-1?
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.
Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer.
Angiopoietin pathway gene expression associated with poor breast cancer survival.
Angiotensin II Type 1 Receptor (AT-1R) Expression Correlates with VEGF-A and VEGF-D Expression in Invasive Ductal Breast Cancer.
Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro.
Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants.
Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells.
Anti-angiogenic potential of Gleditsia sinensis fruit extract.
Anti-cancer effects of Piper nigrum via inducing multiple molecular signaling in vivo and in vitro.
Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting.
Antiangiogenic effects of melatonin in endothelial cell cultures.
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
Apatinib for molecular targeted therapy in tumor.
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation.
Apatinib-induced hyperammonemic encephalopathy.
Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells.
Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential.
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Association between the Functional Polymorphism of Vascular Endothelial Growth Factor Gene and Breast Cancer: A Meta-Analysis.
Association between vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 18 case-control studies.
Association Between Vascular Endothelial Growth Factor Gene Polymorphisms with Breast Cancer Risk in an Iranian Population.
Association of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene with sporadic breast cancer in North Indians.
Association of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in north Indian patients.
Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis.
Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis.
Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction.
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.
Association of vascular endothelial growth factor single nucleotide polymorphisms on the prognosis of breast cancer patients.
Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians.
Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer.
Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.
Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.
Bevacizumab for advanced breast cancer.
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.
Bevacizumab in metastatic breast cancer: when may it be used?
Bevacizumab in the treatment of metastatic breast cancer.
Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI.
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Bevacizumab: in first-line treatment of metastatic breast cancer.
Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
Blocking ?v?3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.
Blood Oxygenation Level-dependent Magnetic Resonance Imaging of Breast Cancer: Correlation with Carbonic Anhydrase IX and Vascular Endothelial Growth Factor.
Breast cancer brain metastases.
Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells.
Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.
Breast tumor cells primed by endoplasmic reticulum stress remodel macrophage phenotype.
Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
c-Kit-Positive Adipose Tissue-Derived Mesenchymal Stem Cells Promote the Growth and Angiogenesis of Breast Cancer.
Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: Implications for tumor angiogenesis.
Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer.
CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.
CCN1 promotes vascular endothelial growth factor secretion through ?v? 3 integrin receptors in breast cancer.
CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo.
Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells.
Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer.
Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma.
Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation.
Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course.
Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer.
Clinical implications of the interleukin 27 serum level in breast cancer.
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Clinical significance of determination of surrogate markers of angiogenesis in breast cancer.
Clinical significance of survivin and vascular endothelial growth factor mRNA detection in the peripheral whole blood of breast cancer patients.
Clinical Study of Tumor Angiogenesis and Perfusion Imaging Using Multi-slice Spiral Computed Tomography for Breast Cancer.
Clinicopathologic and prognostic characteristics of triple-negative breast cancer.
Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications.
Co-expression of ?9?1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN.
Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat.
Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma.
Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.
Combinational Polymorphisms of Seven CXCL12-Related Genes Are Protective against Breast Cancer in Taiwan.
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer.
Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma.
Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells.
Complex influence of dermatan sulphate on breast cancer cells.
Compounds in clinical Phase III and beyond.
Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer.
Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.
Correlation between hepatocyte growth factor receptor and vascular endothelial growth factor-A in breast carcinoma.
Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer.
Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma.
Correlation between ultrasonic features and expression levels of C-erbB-2, VEGF and nm23 in breast cancer.
Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma.
Correlation between VEGF expression and angiogenesis in breast carcinoma.
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
Correspondence re: K. Heer et al., serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res., 7: 3491-3494, 2001.
COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer.
Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.
Crosstalk between IGF signaling and steroid hormone receptors in breast cancer.
Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells.
Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression.
Current evidences on vascular endothelial growth factor polymorphisms and breast cancer susceptibility.
CXCL7-Mediated Stimulation of Lymphangiogenic Factors VEGF-C, VEGF-D in Human Breast Cancer Cells.
Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
Cyclin I correlates with VEGFR-2 and cell proliferation in human epithelial ovarian cancer.
Cytokine gene polymorphisms and breast cancer susceptibility and prognosis.
Dauricine inhibits insulin-like growth factor-I-induced hypoxia inducible factor 1alpha protein accumulation and vascular endothelial growth factor expression in human breast cancer cells.
Decorin Antagonizes the Angiogenic Network: CONCURRENT INHIBITION OF MET, HYPOXIA INDUCIBLE FACTOR 1?, VASCULAR ENDOTHELIAL GROWTH FACTOR A, AND INDUCTION OF THROMBOSPONDIN-1 AND TIMP3.
Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells.
Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.
Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma.
Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinoma.
Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.
Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy.
Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.
Differential stimulation of VEGF-C production by adhesion/growth-regulatory galectins and plant lectins in human breast cancer cells.
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer?
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis.
Downregulation of ERR? inhibits angiogenesis in human umbilical vein endothelial cells through regulating VEGF production and PI3K/Akt/STAT3 signaling pathway.
Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.
Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma.
Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.
Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells.
Effect of anesthetic technique on serum vascular endothelial growth factor C and transforming growth factor ? in women undergoing anesthesia and surgery for breast cancer.
Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.
Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells.
Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/?-catenin pathway.
Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women.
Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients.
Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells.
Effects of a Weight Loss Intervention on Body Mass, Fitness, and Inflammatory Biomarkers in Overweight or Obese Breast Cancer Survivors.
Effects of brucine on vascular endothelial growth factor expression and microvessel density in a nude mouse model of bone metastasis due to breast cancer.
Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Effects of PPAR? agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.
Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
EGCG decreases the expression of HIF-1? and VEGF and cell growth in MCF-7 breast cancer cells.
Elevated plasma levels of tissue factor as a valuable diagnostic biomarker with relevant efficacy for prediction of breast cancer morbidity.
Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.
Emerging targeted therapies for breast cancer.
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer.
Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II.
Enhancement of vascular endothelial growth factor release in long-term drug-treated breast cancer via transient receptor potential channel 5-Ca(2+)-hypoxia-inducible factor 1? pathway.
Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells.
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells.
ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma.
Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer.
Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins.
Estrogen regulation of VEGF in breast cancer in vitro and in vivo: the role of estrogen receptor {alpha} and c-Myc.
Estrogen-related receptor ? expression and function are associated with vascular endothelial growth factor in human cervical cancer.
Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells.
Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.
Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice.
Evaluation of cyclin-dependent kinase-like 1 expression in breast cancer tissues and its regulation in cancer cell growth.
Evaluation of lymphangiogenic factors, vascular endothelial growth factor d and e-cadherin in distinguishing inflammatory from locally advanced breast cancer.
Evaluation of microcirculation of thyroid cancer in Chinese females with breast cancer using contrast-enhanced ultrasound (CEUS) combined with VEGF and microvessel density (MVD).
Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer--10 years follow-up analysis.
Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients.
Evaluation of the correlation between colour power Doppler flow imaging and vascular endothelial growth factor in breast cancer.
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.
Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).
Evaluation of Vascular Endothelial Growth Factor as a Prognostic Marker for Local Relapse in Early-Stage Breast Cancer Patients Treated with Breast-Conserving Therapy.
Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor.
Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Expression of breast cancer anti-estrogen resistance 1 in relation to vascular endothelial growth factor, p53, and prognosis in esophageal squamous cell cancer.
Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance.
Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer.
Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
Expression of Metallothionein and Vascular Endothelial Growth Factor Isoforms in Breast Cancer Cells.
Expression of the pro-angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 by human breast carcinomas is responsive to nutrient deprivation and endoplasmic reticulum stress.
Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
Expression of vascular endothelial growth factor and caspase-3 in mucinous breast carcinoma and infiltrating ductal carcinoma-not otherwise specified, and the correlation with disease-free survival.
Expression of vascular endothelial growth factor and E26 transformation-specific-1 in breast carcinoma.
Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer.
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas.
Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas.
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer.
Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.
Expression profile of IL-8 and growth factors in breast cancer cells and adipose-derived stem cells (ASCs) isolated from breast carcinoma.
Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.
Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: A meta-analysis involving 16,703 individuals.
Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo.
Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts.
Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Forkhead box protein k1 recruits TET1 to act as a tumor suppressor and is associated with MRI detection.
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
FOXP3 inhibits angiogenesis by downregulating VEGF in breast cancer.
Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer.
Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study.
GPER mediates activation of HIF1?/VEGF signaling by estrogens.
GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin ?5?1 for efficient breast cancer metastasis.
Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.
Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells.
HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer.
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Hexachlorobenzene promotes angiogenesis in vivo, in a breast cancer model and neovasculogenesis in vitro, in the human microvascular endothelial cell line HMEC-1.
Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2.
High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer.
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.
High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer.
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer.
High-circulating Tie2 is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer.
Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer.
HTERT mRNA expression correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human breast cancer: a correlative study using RT-PCR.
Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.
Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens.
Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients.
Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells.
Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer.
Identification of novel biomarkers in chronic immune thrombocytopenia (ITP) by microarray-based serum protein profiling.
Imazamethabenz inhibits human breast cancer cell proliferation, migration and invasion via combination with Pin1.
Immunohistochemical expression of vascular endothelial growth factor and its correlation with tumor grade in breast ductal carcinoma.
Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor.
Impaired lymphatic function accelerates cancer growth.
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer.
In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways.
In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients.
Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer.
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.
Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.
Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis.
Induction of Ras by SAF-1/MAZ through a feed-forward loop promotes angiogenesis in breast cancer.
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.
Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells.
Influence of VEGF, COX-2, and MMP-9 expression on the molybdenum-targeted X-ray in breast cancer.
Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.
Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs.
Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.
Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells.
Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2.
Inhibition of vascular endothelial growth factor by small interfering RNA upregulates differentiation, maturation and function of dendritic cells.
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
INHIBITORY ACTION OF CoCl2-INDUCED MCF-7 CELL HYPOXIA MODEL OF BREAST CANCER AND ITS INFLUENCE ON VASCULAR ENDOTHELIAL GROWTH FACTOR.
Insights into the targeting potential of thymoquinone for therapeutic intervention against triple-negative breast cancer.
Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.
Interleukin 7 upregulates vascular endothelial growth factor D in breast cancer cells and induces lymphangiogenesis in vivo.
Investigating the Antiangiogenic, Anti-drug Resistance and Apoptotic Effects of Soy Isoflavone Extract Alone or in Combination with Docetaxel on Murine 4T1 Breast Tumor Model.
Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case-control study.
Investigation of the therapeutic efficacy of codelivery of psiRNA-vascular endothelial growth factor and pIL-4 into chitosan nanoparticles in the breast tumor model.
Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.
ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis.
JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells.
Lack of association between +405 G/C polymorphism in VEGF and breast cancer risk: A meta-analysis.
Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling.
Leptin signaling in breast cancer: an overview.
LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.
Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.
Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.
Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
Lunasin Attenuates Obesity-Associated Metastasis of 4T1 Breast Cancer Cell through Anti-Inflammatory Property.
Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts.
Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases.
Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature.
Magnetic fluid hyperthermia inhibits the growth of breast carcinoma and downregulates vascular endothelial growth factor expression.
Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant.
Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression.
Measurement of serum vascular endothelial growth factor in breast cancer patients.
Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration.
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Metastatic breast cancer: an updating.
Metformin Inhibits Advanced Glycation End Products (AGEs)-induced Growth and VEGF Expression in MCF-7 Breast Cancer Cells by Suppressing AGEs Receptor Expression via AMP-activated Protein Kinase.
Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2.
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells.
Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells.
miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells.
miR-27a regulates endothelial differentiation of breast cancer stem like cells.
miR-342 is associated with estrogen receptor-? expression and response to tamoxifen in breast cancer.
MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis.
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.
Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer.
Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress.
Molecular targeted therapies for breast cancer treatment.
Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells.
Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPAR?.
N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients.
Need for clarification of data in a recent meta-analysis on vascular endothelial growth factor (VEGF) and risk of breast cancer.
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis.
Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues.
New targeted therapies in breast cancer.
No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery.
Non-angiogenic functions of VEGF in breast cancer.
Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.
Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis and growth of breast cancer in female mice.
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma.
Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer.
Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancer.
Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.
Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.
Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo.
p16 Modulates VEGF Expression via Its Interaction With HIF-1alpha in Breast Cancer Cells.
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma.
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
Paired box 5 is a novel marker of breast cancers that is frequently downregulated by methylation.
Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Peripheral enhancement of breast cancers on contrast-enhanced ultrasound: correlation with microvessel density and vascular endothelial growth factor expression.
Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients.
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab.
Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells.
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer.
Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer.
Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer.
Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.
Plasmonic droplet screen for single-cell secretion analysis.
Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer.
Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways.
Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis.
Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort.
Potential Impact of Vascular Endothelial Growth Factor Gene Variation (-2578C>A) on Breast Cancer Susceptibility in Saudi Arabia: a Case-Control Study
Prediction model of lymphovascular invasion based on clinicopathological factors in Chinese patients with invasive breast cancer.
Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue.
Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.
Predictors of lymphovascular invasion identified from pathological factors in Chinese patients with breast cancer.
Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo.
Preoperative assessment of tumor angiogenesis by vascular endothelial growth factor mRNA expression in homogenate samples of breast carcinoma: fine-needle aspirates vs. resection samples.
Prevalence of +405G>C,-1154G>A Vascular Endothelial Growth Factor Polymorphism in Breast Cancer.
Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.
Progesterone in Breast Cancer Angiogenesis.
Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.
Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy.
Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial.
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer.
Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer.
Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis.
Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
Prognostic value of vascular endothelial growth factor in breast cancer.
Progranulin expression in breast cancer with different intrinsic subtypes.
Progress in targeted therapy for breast cancer.
Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects.
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Promising molecular targeted therapies in breast cancer.
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways.
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.
Quantitation of Vascular Endothelial Growth Factor and Interleukin-6 in Different Stages of Breast Cancer.
Quantitation of vascular endothelial growth factor mRNA levels in human breast tumors and metastatic lymph nodes.
Quantitative analysis of vascular endothelial growth factor in primary breast cancer.
Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis.
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors.
Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis.
Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.
Regenerative Therapy and Cancer: In Vitro and In Vivo Studies of the Interaction Between Adipose-Derived Stem Cells and Breast Cancer Cells from Clinical Isolates.
Regulation of endothelial growth factor expressions in breast cancer.
Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells.
Regulation of transcription of hypoxia-inducible factor-1? (HIF-1?) by heat shock factors HSF2 and HSF4.
Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells.
Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide & urokinase-type plasminogen activator in breast cancer patients.
Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer.
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines.
Retraction: Correlation of serum intercellular adhesion molecule 1 and vascular endothelial growth factor with tumor grading and staging in breast cancer patients.
Revaluation of the association between vascular endothelial growth factor gene 936 C/T polymorphism and breast cancer risk.
RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
RNAi-mediated gene silencing of vascular endothelial growth factor C suppresses growth and induces apoptosis in mouse breast cancer in vitro and in vivo.
Role of NF-?B activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells.
Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts.
Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines.
Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion.
Role of vascular endothelial growth factor during breast cancer.
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.
Role of vascular endothelial growth factor-C and -D mRNA in breast cancer.
Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.
Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models.
Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect.
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients.
Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancer.
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
Serum vascular endothelial growth factor in breast cancer.
Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Serum Vascular Endothelial Growth Factors A, C and D in Human Breast Tumors.
Sesamin Inhibits Macrophage-Induced Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Expression and Proangiogenic Activity in Breast Cancer Cells.
Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.
Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients.
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer.
Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: correlation with carbohydrate antigen 15.3.
Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging.
Soluble vascular endothelial growth factor receptors 2 (sVEGFR-2) and 3 (sVEGFR-3) and breast cancer risk in the Swedish Mammography Cohort.
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer.
Sulfatase 2 facilitates lymphangiogenesis in breast cancer by regulating VEGF-D.
Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models.
Suppression of vascular endothelial growth factor expression in breast cancer cells by microRNA-125b-mediated attenuation of serum amyloid A activating factor-1 level.
Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells.
Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ER? and VEGFR-2.
Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.
Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo.
Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
Targeted drugs and Psycho-oncological intervention for breast cancer patients.
Targeted Therapies for Brain Metastases from Breast Cancer.
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Targeting angiogenesis with antibodies for the treatment of cancer.
Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis.
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.
Targeting Notch1 inhibits invasion and angiogenesis of human breast cancer cells via inhibition Nuclear Factor-?B signaling.
Tea phytochemicals for breast cancer prevention and intervention: From bench to bedside and beyond.
The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake.
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.
The Association Between VEGF +936C/T and -634G/C Polymorphisms and Breast Cancer Susceptibility, Tumor Growth, and Metastases: Evidence From 20,728 Subjects.
The Association of Serum IL-33 and sST2 with Breast Cancer.
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts.
The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
The correlation between immunohistochemically-detected markers of angiogenesis and serum vascular endothelial growth factor in patients with breast cancer.
The Determination of VEGF and MVD, among Patients with Primary Breast Cancer.
The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas.
The effect of cancer procoagulant on expression of metastatic and angiogenic markers in breast cancer and embryonic stem cell lines.
The effect of exercise training on the level of tissue IL-6 and vascular endothelial growth factor in breast cancer bearing mice.
The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
The effect of vascular endothelial growth factor C expression in tumor-associated macrophages on lymphangiogenesis and lymphatic metastasis in breast cancer.
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer.
The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer.
The expression of ER beta protein correlates with vascular endothelial growth factor and its prognostic significance in human breast cancer.
The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.
The life, death, and attempted rebirth of bevacizumab in breast cancer.
The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells.
The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer.